Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
Montefiore Medical Center, Bronx, New York, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center, Columbus, Ohio, United States
Mayo Clinic, Rochester, Minnesota, United States
Institute of Drug Development, Cancer Therapy Research Center, San Antonio, Texas, United States
University of Michigan Medical School, Ann Arbor, Michigan, United States